We are live on ! Find out more
GILD icon

Gilead Sciences

1,504 hedge funds and large institutions have $81.5B invested in Gilead Sciences in 2017 Q3 according to their latest regulatory filings, with 123 funds opening new positions, 601 increasing their positions, 613 reducing their positions, and 124 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $69.4B → $81.5B (+$12.2B)

8% more funds holding in top 10

Funds holding in top 10: 8996 (+7)

2.03% more ownership

Funds ownership: 74.96%76.99% (+2%)

1% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 124

2% less repeat investments, than reductions

Existing positions increased: 601 | Existing positions reduced: 613

1% less funds holding

Funds holding: 1,5201,504 (-16)

28% less call options, than puts

Call options by funds: $1.87B | Put options by funds: $2.61B

Holders
1,504
Holders Change
-16
Holders Change %
-1.05%
% of All Funds
37.49%
Holding in Top 10
96
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+7.87%
% of All Funds
2.39%
New
123
Increased
601
Reduced
613
Closed
124
Calls
$1.87B
Puts
$2.61B
Net Calls
-$732M
Net Calls Change
-$83M
Name Holding Trade Value Shares
Change
Change in
Stake
EWM
376
Edge Wealth Management
New York
$11M -$278K -3,637 -3%
DnB Asset Management
377
DnB Asset Management
Norway
$10.9M -$8.86M -115,900 -46%
AIM
378
Assured Investment Management
New York
$10.8M +$1.65M +21,595 +19%
SAM
379
Securian Asset Management
Minnesota
$10.7M +$60K +785 +0.6%
BIM
380
Bogle Investment Management
Massachusetts
$10.6M +$10M +131,376 New
RS
381
Robeco Schweiz
Switzerland
$10.6M -$1.95M -25,455 -16%
CI
382
Conning Inc
Connecticut
$10.5M -$889K -11,630 -8%
GD
383
Grandfield & Dodd
New York
$10.4M +$2M +26,167 +26%
TAM
384
Tocqueville Asset Management
New York
$10.4M +$7.1M +92,796 +264%
CSIC
385
Clifford Swan Investment Counsel
California
$10.4M -$270K -3,535 -3%
CM
386
Capital Management
Virginia
$10.3M +$2.29K +30 +0%
WAM
387
World Asset Management
Michigan
$10.2M -$43.2K -565 -0.4%
TA
388
Tamarack Advisers
California
$10.1M -$765K -10,000 -7%
FI
389
Fosun International
China
$10M
ACPU
390
Arrowgrass Capital Partners (US)
Delaware
$10M +$8.06M +105,342 +578%
Jacobs Levy Equity Management
391
Jacobs Levy Equity Management
New Jersey
$9.96M -$14.5M -189,656 -61%
IBT
392
International Biotechnology Trust
United Kingdom
$9.95M +$76.5K +1,000 +0.8%
NMERB
393
New Mexico Educational Retirement Board
New Mexico
$9.84M
LKIM
394
Lawson Kroeker Investment Management
Nebraska
$9.75M -$40.5K -530 -0.4%
AFG
395
American Financial Group
Ohio
$9.72M
Mirae Asset Global Investments
396
Mirae Asset Global Investments
South Korea
$9.66M +$2.17M +28,339 +31%
CM
397
Castleark Management
Illinois
$9.63M +$8.41M +109,968 +1,243%
WAM
398
Wilsey Asset Management
California
$9.61M -$310K -4,051 -3%
FWM
399
Frontier Wealth Management
Missouri
$9.55M -$1.2M -15,744 -12%
FT
400
Fiduciary Trust
Massachusetts
$9.54M -$1.07M -13,977 -11%

GILD Hedge Fund Activity: Q3 2017 in Review

1,504 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2017, worth a combined $81.5B — up 18% from $69.4B a quarter earlier.

Sellers outnumbered buyers: 124 funds closed out of GILD and 123 opened new positions — a net loss of 1 holder — while 613 trimmed existing stakes and 601 added.

The largest buyer was Dodge & Cox, adding an estimated $758M. The largest seller was Susquehanna International Group, cutting an estimated $359M.

  • 1,504 institutional investors held Gilead Sciences (GILD) as of Q3 2017, down from 1,520 in Q2 2017.
  • Funds reported $81.5B of Gilead Sciences stock for Q3 2017, up 18% quarter-over-quarter.
  • 123 funds opened new Gilead Sciences positions in Q3 2017 and 124 closed out, a net change of -1 holder.
  • The largest Gilead Sciences buyer in Q3 2017 was Dodge & Cox, an estimated $758M added.
  • The largest Gilead Sciences seller in Q3 2017 was Susquehanna International Group, an estimated $359M sold.

Based on aggregated 13F filings for Q3 2017.